Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.

Zacks Investment Research • May 7, 2026

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • May 7, 2026

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.

PRNewsWire • May 7, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

GlobeNewsWire • May 5, 2026

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 29, 2026

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each,.

Business Wire • Apr 20, 2026

Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.

GlobeNewsWire • Apr 7, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:  APLS ) related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.

PRNewsWire • Apr 1, 2026

Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?

Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Apr 1, 2026

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.

Zacks Investment Research • Apr 1, 2026